背景:罗沙司他治疗肾性贫血的药理机制。
方法:探讨罗沙司他与红细胞生成刺激剂(ESA)联合治疗血液透析患者继发性甲状旁腺功能亢进的肾性贫血的疗效和安全性。
方法:对单纯ESAs治疗的肾性贫血合并继发性甲状旁腺功能亢进的血液透析患者进行回顾性分析,他们于2022年3月至2022年12月入院。
方法:患者接受罗沙司他联合ESAs治疗3个月,在此期间给予口服铁补充剂,分析联合治疗前后Hb水平及实验室相关指标的变化。
结果:结果显示,共有13名患者接受了联合治疗,与单独的ESA相比,Hb显着增加(t=-3.955,P=0.002)。Hb合格率为38.46%,ΔHb反应率为76.92%。甲状旁腺激素显著下降,差异有统计学意义(Z=-2.0162b,P=.039)。血红蛋白(RBC),总铁结合能力,与单独的ESA相比,血清铁蛋白(男性)显着增加。总胆固醇和低密度脂蛋白明显低于单独的ESA。上述指标变化差异均有统计学意义(P<0.05)。其他实验室相关指标变化差异无统计学意义(P>.05)。13例患者在联合治疗期间未观察到不良反应。
■罗沙司他与ESAs联合使用可有效改善继发性甲状旁腺功能亢进的血液透析患者的肾性贫血,以及改善甲状旁腺功能亢进指标和血脂水平具有较高的安全性。因此,这种联合治疗为这些患者提供了一种新的安全治疗方法。
BACKGROUND: Pharmacological mechanism of Roxadustat in the treatment of renal anemia.
METHODS: To investigate the efficacy and safety of combined Roxadustat and erythropoiesis stimulator (ESA) treatment of renal anemia in hemodialysis patients with secondary hyperparathyroidism.
METHODS: A retrospective analysis was conducted on hemodialysis patients with renal anemia and secondary hyperparathyroidism treated with ESAs alone, who were admitted to our hospital from March 2022 to December 2022.
METHODS: The patients were treated with Roxadustat combined with ESAs for 3 months, during which oral iron supplementation was given, and the changes in Hb levels and laboratory-related indicators before and after the combined treatment were analyzed.
RESULTS: The results showed that a total of 13 patients received combination therapy, with a significant increase in Hb compared to ESAs alone (t = -3.955, P = .002). The Hb qualification rate was 38.46%, and the ∆Hb response rate was 76.92%. The parathyroid hormone significantly decreased with a statistically significant difference (Z = -2.062b, P = .039). Hemoglobin (RBC), total iron binding capacity, and serum ferritin (male) were significantly increased compared to ESAs alone. Total cholesterol and low-density lipoprotein were significantly lower than ESAs alone. The differences in the changes in the above indicators were statistically significant (P < .05). There was no statistically significant difference in changes in other laboratory-related indicators (P > .05). No adverse reactions were observed during the combined treatment of 13 patients.
UNASSIGNED: The combination of Roxadustat and ESAs can effectively improve renal anemia in hemodialysis patients with secondary hyperparathyroidism, as well as improve indicators of hyperparathyroidism and blood lipid levels with high levels of safety. This combined treatment thus provides a new and safe treatment method for these patients.